###begin article-title 0
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
Metabolomic Profiling in LRRK2-Related Parkinson's Disease
###end article-title 0
###begin p 1
Conceived and designed the experiments: JOA MFB MB. Performed the experiments: KKJ LW MB. Analyzed the data: LW MB. Contributed reagents/materials/analysis tools: KKJ JOA LRW WM CH. Wrote the paper: LW MB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
Mutations in LRRK2 gene represent the most common known genetic cause of Parkinson's disease (PD).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 174 186 174 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S LRRK2</italic>
###xml 269 281 269 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S LRRK2</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 831 836 831 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
###xml 704 712 <span type="species:ncbi:9606">patients</span>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
###xml 1073 1081 <span type="species:ncbi:9606">patients</span>
We used metabolomic profiling to identify biomarkers that are associated with idiopathic and LRRK2 PD. We compared plasma metabolomic profiles of patients with PD due to the G2019S LRRK2 mutation, to asymptomatic family members of these patients either with or without G2019S LRRK2 mutations, and to patients with idiopathic PD, as well as non-related control subjects. We found that metabolomic profiles of both idiopathic PD and LRRK2 PD subjects were clearly separated from controls. LRRK2 PD patients had metabolomic profiles distinguishable from those with idiopathic PD, and the profiles could predict whether the PD was secondary to LRRK2 mutations or idiopathic. Metabolomic profiles of LRRK2 PD patients were well separated from their family members, but there was a slight overlap between family members with and without LRRK2 mutations. Both LRRK2 and idiopathic PD patients showed significantly reduced uric acid levels. We also found a significant decrease in levels of hypoxanthine and in the ratios of major metabolites of the purine pathway in plasma of PD patients.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
These findings show that LRRK2 patients with the G2019S mutation have unique metabolomic profiles that distinguish them from patients with idiopathic PD. Furthermore, asymptomatic LRRK2 carriers can be separated from gene negative family members, which raises the possibility that metabolomic profiles could be useful in predicting which LRRK2 carriers will eventually develop PD. The results also suggest that there are aberrations in the purine pathway in PD which may occur upstream from uric acid.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 142 155 142 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2, Parkin</italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PINK1</italic>
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Hardy1">[1]</xref>
###xml 255 258 255 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Thomas1">[4]</xref>
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6055G&#8202;&gt;A</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 422 425 422 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bras1">[5]</xref>
###xml 426 429 426 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Ozelius1">[7]</xref>
###xml 574 577 574 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Aasly1">[8]</xref>
Parkinson's disease (PD) was long considered to be largely idiopathic, but several genetic factors have been reported during the last decade. LRRK2, Parkin and PINK1 genes have the most clinical relevance because of their comparatively high frequency [1]-[4]. The 6055G >A mutation in the LRRK2 gene, resulting in a G2019S substitution in the LRRK2 protein is common, though the frequency varies dependent on ethnic group [5]-[7]. In central Norway, about 3% of all PD cases have been found to carry this mutation, although the penetrance in affected families is incomplete [8].
###end p 9
###begin p 10
###xml 360 363 360 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Brucke1">[9]</xref>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Kim1">[10]</xref>
The discovery of PD genes has greatly improved our understanding of PD and could possibly provide new strategies for treatment. The diagnosis of PD is still mainly based on clinical features, and a definitive diagnosis can only be confirmed by autopsy findings. Disease progression can be followed with functional neuroimaging techniques such as PET and SPECT [9], [10], but these techniques have limited availability, are expensive, and are not used in daily clinical practice.
###end p 10
###begin p 11
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-LeWitt1">[11]</xref>
###xml 293 297 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-ElAgnaf1">[12]</xref>
###xml 299 303 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Tokuda1">[13]</xref>
###xml 467 471 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 473 477 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Scherzer1">[15]</xref>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Several biochemical markers have been assessed as potential biomarkers, such as dopamine metabolites in the CSF of PD patients, but do not correlate with PD severity [11]. Decreased levels of alpha-synuclein in CSF, and an elevated level of the oligomeric protein in plasma have been reported [12], [13], but neither is recognized as a diagnostic marker. Several studies are currently in progress to find biomarkers using genomic, proteomic or metabolomic approaches [14], [15].
###end p 11
###begin p 12
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Goodacre1">[16]</xref>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Brindle1">[17]</xref>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Griffin1">[18]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-DiLeo1">[19]</xref>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Holmes1">[20]</xref>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Rozen1">[21]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Underwood1">[22]</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 453 461 <span type="species:ncbi:9606">patients</span>
Metabolomics is the comprehensive analysis of low molecular weight molecules within a particular biological sample, followed by organization for data mining and bioinformatics [16], and has been used to study several illnesses, including heart disease [17], type 2 diabetes [18], cancer [19], and nervous system diseases such as schizophrenia [20], amyotrophic lateral sclerosis [21], and Huntington's disease [22]. We recently found that idiopathic PD patients have metabolomic phenotypes which differ from control subjects [14].
###end p 12
###begin p 13
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 80 83 80 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Aasly1">[8]</xref>
###xml 85 89 85 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Goldwurm1">[23]</xref>
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Khan1">[24]</xref>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
Clinically, LRRK2 PD patients are indistinguishable from idiopathic PD patients [8], [23], [24]. Genotyping can differentiate between LRRK2 and idiopathic PD patients after onset of clinical symptoms. However, it provides incomplete information about possible development of PD in asymptomatic gene carriers, due to incomplete penetrance. Therefore, it is important to find biomarkers in mutation carriers which may predict the development of the clinical symptoms.
###end p 13
###begin p 14
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 136 148 136 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2 G2019S</italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
In the present study we used a metabolomics approach to define plasma metabolomes associated with LRRK2 PD, idiopathic PD, asymptomatic LRRK2 G2019S carriers, and normal control subjects. Both untargeted and targeted (including 34 major known metabolites of the purines, tyrosine, and tryptophan pathways) approaches were performed to thoroughly investigate the differences between LRRK2 and idiopathic PD, as well as between controls and all PD patients.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 16
###begin p 17
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 515 527 515 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2 G2019S</italic>
###xml 570 577 570 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t001">Table 1</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Gelb1">[25]</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
###xml 758 766 <span type="species:ncbi:405018">cardinal</span>
A total of 99 subjects were enrolled in this study: PD patients without any known mutations (idiopathic, n = 41) and PD patients carrying the G2019S mutation in LRRK2 gene (n = 12). The healthy family members from the mutation carrier PD cases were invited to participate in this study and 21 of them tested positive for the mutation (mut+) and 10 of them were negative (mut-). Additionally, 15 control subjects who were healthy with no signs of any movement disorder, and were not in the family or a spouse of the LRRK2 G2019S cases, were recruited from the same area. Table 1 presents the demographic data. All the PD patients were examined and followed up by one neurologist (J.O.A.). Clinical criteria for diagnosis required the presence of at least two cardinal motor signs: asymmetric resting tremor, bradykinesia and rigidity, as well as a good response to levodopa and absence of other atypical features and causes of parkinsonism [25]. A complete neurological examination was performed on the healthy family members without any clinical signs of parkinsonism.
###end p 17
###begin title 18
The clinical data of the enrolled subjects.
###end title 18
###begin p 19
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Idiopathic PD: patients without any known mutations; LRRK2 PD: patients carrying the G2019S mutation in LRRK2; Mut+: healthy family members with G2019S mutation in LRRK2; Mut-: healthy family members without mutation; Controls: healthy subjects without any sign of neurological diseases; AAO: age at disease onset.
###end p 19
###begin p 20
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 548 555 548 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t002">Table 2</xref>
###xml 632 637 632 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
All the patients included in this study were tested for known PD-related mutations and none of the patients with idiopathic PD were found to have any such mutations. The 12 LRRK2 PD patients were heterozygous carriers for the G2019S mutation, from 9 unrelated families. The treatment of the two PD groups consisted for the most part of a combination of levodopa and dopamine agonists, but 8 idiopathic patients used selegiline, and 3 used antipsychotic medicines. No patients with the mutation were treated with the latter two types of medication. Table 2 shows a list of the medications used by the patients. The family members of LRRK2 PD patients were screened specifically for the G2019S mutation, as were the healthy control subjects. The mutation was not found in any of the controls, but was found in twenty one family members.
###end p 20
###begin title 21
###xml 21 29 <span type="species:ncbi:9606">patients</span>
The medication of PD patients.
###end title 21
###begin p 22
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 104 111 <span type="species:ncbi:9606">patient</span>
###xml 167 174 <span type="species:ncbi:9606">patient</span>
Dosages of dopamine agonist are calculated in levodopa equivalent dosages, LEDD. One de novo idiopathic patient was without any medication; total number of idiopathic patient is 41.
###end p 22
###begin title 23
Ethics statement
###end title 23
###begin p 24
Written informed consent was acquired from all subjects participating in this study, according to the declaration of Helsinki. The study was approved by the Regional Committee for Medical Research Ethics, Central Norway. The protocol for analysis of the samples at the Bedford VAMC was approved by the Bedford VAMC IRB.
###end p 24
###begin title 25
Sample preparation and analysis
###end title 25
###begin p 26
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Rozen1">[21]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Kristal1">[26]</xref>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-VigneauCallahan1">[28]</xref>
###xml 1260 1264 1260 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Kristal1">[26]</xref>
###xml 1266 1270 1266 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Kristal2">[29]</xref>
Plasma samples were prepared for analysis by extraction in acidified acetonitrile and analyzed by LCECA as previously described [14], [21], [26]-[28]. During the sample preparation, pools were created from equal volumes of subaliquots of all samples in the study. Pools and duplicates were used to assess the precision of the entire data set and to control the overall performance of the analytical method. The pools also served as references for time normalization (peak stretching) and were used to express the concentrations of each peak in the samples as a percentage of the concentration of those peaks in the averaged pool. The replicate analyses of the pool also provided an estimate of the coefficient of variation associated with each peak, that is, the standard deviation of the peak height across pool replicates normalized to mean peak height. Peaks included in the further data analysis were those that had good precision in the replicate analyses of the pool. 712 were judged to meet this criterion and used for the further data analysis. These 712 analytes included both unknown and known compounds, comprising metabolites of tyrosine, tryptophan and purine pathways, and some redox active markers of oxidative stress, antioxidants and vitamins [26], [29].
###end p 26
###begin title 27
Data analysis
###end title 27
###begin p 28
###xml 70 74 70 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Eriksson1">[30]</xref>
###xml 840 844 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Broadhurst1">[31]</xref>
###xml 952 957 952 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1045 1046 1045 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 961 969 <span type="species:ncbi:9606">patients</span>
All chromatograms in the study were processed as previously described [14]. The levels of all analytes were normalized to the averaged pool and expressed as the percentage of those analytes in the pool. Conventional statistical methods and projection to latent structures- discriminant analysis (PLS-DA) [30], were used for the data analysis. Both unprocessed and preprocessed datasets were used for PLS-DA. To avoid possible statistical artifacts, and to find the analytes (potential biomarkers) which can be used to build PLS-DA models for class discrimination and class membership prediction, we used a preprocessing approach. For this, Student's t-tests followed by the area under the Receiver Operating Characteristic (ROC) curve were used. The ROC curve is a plot of the sensitivity (or true-positive rate) to the false-positive rate [31]. Using this approach, values of the analytes in each subgroup were compared to another, e.g., controls vs. LRRK2 PD patients. The criteria for inclusion of analytes into further analysis were set at: p value less than 0.01 and area under the ROC curve larger than 0.8.
###end p 28
###begin p 29
To build and validate PLS-DA models for class discrimination and class membership prediction, data for the subjects from different subgroups were randomly divided into the training (approximately2/3 of all subjects in a given subgroup) and test (approximately1/3 of the subjects) sets. Test sets were excluded from the data pre-processing and model construction. Following construction of PLS-DA models using training sets, the models were then used to predict class membership of the subjects in the test sets. This procedure was repeated four times, different subjects in training and test sets were included and a new PLS-DA model was constructed each time.
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 721 729 721 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g001">Figure 1</xref>
###xml 868 873 868 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 922 930 922 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g001">Figure 1</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
###xml 698 706 <span type="species:ncbi:9606">patients</span>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
In the initial analysis we analyzed the data from control subjects and idiopathic and LRRK2 PD patients to determine if there were any differences in the metabolomic profiles between these groups. Since healthy family members of LRRK2 PD patients without the mutation could be considered as controls, the data from them were also included in this analysis, either separately, or together with control subjects. All peaks detected (unprocessed datasets) were used for the initial analysis. Using PLS-DA we found complete separation between both groups of PD patients and controls. PLS-DA scores plots showing separation between controls and idiopathic PD patients, and between controls and LRRK2 PD patients, are shown in Figure 1 (panels A and B, respectively). Complete separation was also found when the data from control subjects and from healthy family members of LRRK2 PD patients without the mutation were combined (Figure 1, panels C and D).
###end p 31
###begin title 32
###xml 47 55 <span type="species:ncbi:9606">patients</span>
PLS-DA scores plots of control subjects and PD patients.
###end title 32
###begin p 33
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
PLS-DA scores plots showing a separation between control subjects (n = 15) and idiopathic Parkinson's Disease (IPD) patients (n = 41), and between control subjects (n = 15) and LRRK2 PD patients (n = 12). All peaks (no pre-processing) were used for these analyses. The data from control subjects and from the healthy family members of LRRK2 PD patients without the mutation (n = 10) were used for the analysis either separately (panels A and B), or were combined (panels C and D).
###end p 33
###begin p 34
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 348 356 348 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g002">Figure 2</xref>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 924 930 918 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g002">Fig. 2</xref>
###xml 1003 1008 997 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 1012 1020 <span type="species:ncbi:9606">patients</span>
In order to determine if there were differences in metabolomic profiles associated with the G2019S mutation with and without PD, we next analyzed unprocessed data sets from LRRK2 PD patients and from their family members with and without the mutation. A PLS-DA score plot showing separation between LRRK2 PD patients and family members is shown in Figure 2. PLS-DA showed complete separation between LRRK2 patients and their family members; there was, however, some overlap between family members with and without the mutation. LRRK2 PD patients participating in this study were significantly older than their healthy family members with the mutation (72.8+/-11.2 vs. 55.2+/-14.1 years old, respectively, mean+/-SD, p<0.05). These age differences had no apparent effect on the observed differences in metabolomic profiles, since PLS-DA scores plot didn't show significant separation based on the age of individual subjects (Fig. 2). However, additional studies involving older healthy family members of LRRK2 PD patients, who carry the mutation, are necessary to validate these findings.
###end p 34
###begin title 35
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
PLS-DA scores plots of LRRK2 PD patients and their family members.
###end title 35
###begin p 36
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
PLS-DA scores plot showing a separation between LRRK2 PD patients (n = 12) and their healthy family member with (n = 21) or without (n = 10) the gene mutation. All peaks (no pre-processing) were used for this analysis. Ages of the individual subjects are shown next to their symbols.
###end p 36
###begin p 37
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Rubingh1">[32]</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Westerhuis1">[33]</xref>
###xml 752 753 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1122 1129 1098 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t003">Table 3</xref>
###xml 1214 1222 1190 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g003">Figure 3</xref>
###xml 1291 1299 1267 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g004">Figure 4</xref>
###xml 1487 1492 1457 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1549 1554 1519 1524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1767 1772 1731 1736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1985 1990 1949 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 2157 2166 2115 2124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g005">Figure 5A</xref>
###xml 2199 2204 2157 2162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 2391 2400 2349 2358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g005">Figure 5B</xref>
###xml 2461 2466 2419 2424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 1511 1519 <span type="species:ncbi:9606">patients</span>
###xml 1555 1563 <span type="species:ncbi:9606">patients</span>
###xml 1598 1606 <span type="species:ncbi:9606">patients</span>
###xml 1791 1799 <span type="species:ncbi:9606">patients</span>
###xml 1897 1905 <span type="species:ncbi:9606">patients</span>
###xml 1991 1999 <span type="species:ncbi:9606">patients</span>
###xml 2137 2145 <span type="species:ncbi:9606">patients</span>
###xml 2205 2213 <span type="species:ncbi:9606">patients</span>
###xml 2238 2246 <span type="species:ncbi:9606">patients</span>
###xml 2294 2302 <span type="species:ncbi:9606">patients</span>
###xml 2485 2493 <span type="species:ncbi:9606">patients</span>
In order to find the analytes which could be used to discriminate between idiopathic and LRRK2 PD patients, we then built PLS-DA models, which were used for class separation and membership prediction, using both unprocessed and pre-processed datasets. The PLS-DA model built using unprocessed datasets showed a complete separation between the two groups. Caution should be exercised to avoid potential overfitting of PLS-DA models for finding separation between different groups. Some concerns related to possible overfitting of PLS-DA models when using datasets, which have the number of variables higher than the number of observations, have been published in recent years [32], [33]. Therefore, we pre-processed our datasets using Student's t-test (p value cutoff set at <0.01) followed by the area under the ROC curve (cutoff set at >0.8).Subjects in each group were randomly divided into training and test sets (approximately2/3 and approximately1/3 of all subjects in a given subgroup, respectively). This procedure was carried out four times with different subjects included in the test set each time, 12 analytes (Table 3) were used to build the models. A representative PLS-DA separation plot is shown in Figure 3; the individual prediction plots for all four analyses are shown in Figure 4 (panels A to D). Sensitivity and specificity of this approach were found to be 87.5+/-7.2 and 97.7+/-2.3 (n = 4, mean+/-SEM), respectively. There were significant age differences between LRRK2 and idiopathic PD patients participating in this study; LRRK2 patients were older than the idiopathic PD patients (72.8+/-11.2 vs. 64.8+/-8.4 years old, respectively, mean+/-SD, p<0.02). Therefore, it is possible that the observed separation between metabolomic profiles of LRRK2 and idiopathic PD patients may be attributed to the age differences. To address this possibility we separated idiopathic PD patients into older and younger groups, with age of the older group matching the age of LRRK2 patients (71.4+/-3.3 and 72.8+/-11.2 years old, respectively, mean+/-SD). No separation between the older and the younger groups of idiopathic PD patients was found (Figure 5A). We also analyzed the data for LRRK2 patients and older idiopathic PD patients separately (the younger group of idiopathic PD patients was excluded from the analysis) and found complete separation between these two groups (Figure 5B). These results indicate that differences in metabolomes of LRRK2 and idiopathic PD patients are not affected by age.
###end p 37
###begin title 38
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
PLS-DA scores plots of IPD and LRRK2 PD patients.
###end title 38
###begin p 39
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 145 152 145 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 397 405 397 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g004">Figure 4</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
PLS-DA scores plot showing a significant separation between IPD patients (n = 30) and LRRK2 PD patients (n = 8) using preprocessed datasets (see methods for details). Eleven IPD patients and 4 LRRK2 PD patients were randomly chosen as the test set and were not used in PLS-DA model construction. Class membership of the subjects in the test set was then predicted using this PLS-DA model shown in Figure 4.
###end p 39
###begin title 40
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
PLS-DA prediction plots of IPD patients and LRRK2 PD patients.
###end title 40
###begin p 41
###xml 17 24 17 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t003">Table 3</xref>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 163 171 163 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g003">Figure 3</xref>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
Twelve analytes (Table 3) were used to build PLS-DA separation model, based on randomly selected 30 IPD and 8 LRRK2 PD patients (a representative plot is shown in Figure 3). The resulting models were used to predict class membership of the remaining 11 IPD and 4 LRRK2 PD patients. This procedure was carried out 4 times with different IPD and LRRK2 PD patients included in the test and training sets each time; the results are presented in panels A-D for all four individual models. Predictions were made with a cutoff of 0.5 for class membership. Numbers next to the symbols refer to the sample codes of the subjects.
###end p 41
###begin title 42
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Age effects on metabolomic profiles of IPD patients and LRRK2 PD patients.
###end title 42
###begin p 43
###xml 323 328 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 439 444 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 455 463 439 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g004">Figure 4</xref>
###xml 468 475 452 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t003">Table 3</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
(A) PLS-DA scores plot showing lack of separation between younger (57.3+/-5.6 years old, n = 19, mean+/-SD) and older (71.4+/-3.3 years old, n = 22, mean+/-SD) idiopathic PD patients. (B) PLS-DA scores plot showing a significant separation between older idiopathic PD patients (71.4+/-3.3 years old, n = 22, mean+/-SD) and LRRK2 patients (72.8+/-11.2 years old, n = 12, mean+/-SD). The analytes discriminating between all IPD patients and LRRK2 patients (Figure 4 and Table 3) were used to for the analysis.
###end p 43
###begin title 44
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
Analytes discriminating between idiopathic and LRRK2 PD.
###end title 44
###begin p 45
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
Analytes are defined by their retention time and dominant channel in LCECA profiles. + up-regulated in LRRK2 PD; - down-regulated in LRRK2 PD.
###end p 45
###begin p 46
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 514 521 514 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t004">Table 4</xref>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 809 817 809 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g006">Figure 6</xref>
###xml 901 909 901 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g007">Figure 7</xref>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
We also analyzed the data from control subjects and from asymptomatic LRRK2 mutation carriers to determine if there are specific metabolomic signatures associated with the mutation. Similar to the analysis of idiopathic and LRRK2 PD patients, we used preprocessed datasets to build PLS-DA models for class separation and membership prediction. Subjects in each group were randomly divided into training and test sets. This procedure was repeated four times with different subjects used each time, with 9 analytes (Table 4) used for model building. Interestingly, two of the analytes (80.1-4 and 42.3-13) were found in the groups of peaks discriminating between idiopathic and LRRK2 PD patients and between asymptomatic LRRK2 mutation carriers and controls. A representative PLS-DA separation plot is shown in Figure 6; the prediction plots for asymptomatic mutation carriers and controls are shown in Figure 7 (panels A to D). Sensitivity and specificity of this approach were found to be 85.7+/-1.5 and 70.0+/-5.8 (n = 4, mean+/-SEM), respectively.
###end p 46
###begin title 47
###xml 49 61 49 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S LRRK2</italic>
PLS-DA score plots of controls and subjects with G2019S LRRK2 gene mutation.
###end title 47
###begin p 48
###xml 109 121 109 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S LRRK2</italic>
###xml 408 416 408 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g007">Figure 7</xref>
PLS-DA scores plot showing a significant separation between controls (n = 10) and asymptomatic subjects with G2019S LRRK2 gene mutation (n = 14) using preprocessed datasets. Five controls subjects and seven mutation carriers were randomly selected as the test set and were not used in PLS-DA model construction. Class membership of the subjects in the test set was predicted using this PLS-DA model shown in Figure 7.
###end p 48
###begin title 49
###xml 54 66 54 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S LRRK2</italic>
PLS-DA prediction plots of controls and subjects with G2019S LRRK2 gene mutation.
###end title 49
###begin p 50
###xml 15 22 15 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t004">Table 4</xref>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 169 177 169 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007551-g006">Figure 6</xref>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
Nine analytes (Table 4) were used to build PLS-DA separation model, based on randomly selected 10 controls and 14 LRRK2 gene carriers (a representative plot is shown in Figure 6). The resulting models were used to predict class membership of the remaining 5 controls and 7 LRRK2 gene carriers. This procedure was carried out 4 times with different controls and gene carriers included in the test and training sets each time; the results are presented in panels A-D for all four individual models. Predictions were made with a cutoff of 0.5 for class membership. Numbers next to the symbols refer to the sample codes of the subjects.
###end p 50
###begin title 51
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
Analytes discriminating between LRRK2 mutation carriers and Controls.
###end title 51
###begin p 52
Analytes are defined by their retention time and dominant channel in LCECA profiles.
###end p 52
###begin p 53
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
+ up-regulated in LRRK2 mutation carriers; - down-regulated in LRRK2 mutation carriers.
###end p 53
###begin p 54
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2)</italic>
###xml 696 698 684 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p&lt;</italic>
###xml 734 739 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 860 861 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 871 876 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1211 1215 1199 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 1385 1387 1373 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p&lt;</italic>
###xml 1540 1547 1528 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007551-t005">Table 5</xref>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
###xml 924 932 <span type="species:ncbi:9606">patients</span>
###xml 1031 1039 <span type="species:ncbi:9606">patients</span>
###xml 1247 1255 <span type="species:ncbi:9606">patients</span>
###xml 1331 1339 <span type="species:ncbi:9606">patients</span>
###xml 1530 1538 <span type="species:ncbi:9606">patients</span>
###xml 1580 1588 <span type="species:ncbi:9606">patients</span>
Although the majority of the analytes driving categorical separations between the groups were not known, there were differences in the levels of some known compounds. Similar to our previous report, uric acid (UA) levels were lower in PD patients (both idiopathic and LRRK2) compared to controls (18% decrease, p<0.01). There was a slight non-significant approximately10% decrease in UA levels in asymptomatic mutation carriers, compared to controls; more samples from the asymptomatic mutation carriers should be analyzed to determine whether UA levels are significantly decreased in these subjects. Hypoxanthine levels were significantly decreased in the asymptomatic mutation carriers by 25% (p<0.05), but not in the idiopathic or LRRK2 PD patients, when compared to control subjects. We also found that xanthine levels were significantly decreased by 18% (p<0.05) in LRRK2 PD patients compared to controls. Since all PD patients participating in this study were on antiparkinsonian medications, it is possible that in these PD patients, levels of purine metabolites could be affected by the antiparkinsonian treatments. To address this possibility, we reanalyzed part of the samples from our previous study [14], which involved unmedicated PD patients, and found a significant decrease in hypoxanthine levels in unmedicated PD patients, compared to control subjects (45% decrease, p<0.05; n = 15 and n = 20, respectively). Levels and ratios of some other purine metabolites were also significantly decreased in unmedicated PD patients (Table 5). Analysis of the data from the patients on different antiparkinsonian medications showed normalization of plasma hypoxanthine levels with levodopa and with combination of levodopa with dopamine receptor agonists.
###end p 54
###begin title 55
Purine metabolites in PD.
###end title 55
###begin p 56
###xml 155 160 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
Data are represented as mean+/-SEM of percentage of plasma pool value. Control group includes both normal control subjects and healthy family members from LRRK2 PD patients who did not have G2019S mutation. HX-hypoxanthine, X-xanthosine, XAN-xanthine, UA-uric acid, G- guanosine.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 159 162 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Hardy1">[1]</xref>
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Thomas1">[4]</xref>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 533 539 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Healy1">[34]</xref>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 725 728 725 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Aasly1">[8]</xref>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Goldwurm1">[23]</xref>
###xml 736 740 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Khan1">[24]</xref>
###xml 810 816 810 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 830 833 830 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Aasly1">[8]</xref>
###xml 953 958 953 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1046 1052 1046 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
The role of genetic factors in the pathogenesis of PD has been proven during the last several years, and several mutations have been implicated in familial PD [1]-[4]. Although these may account for a relatively small percentage of all PD cases, analysis of the pathogenetic mechanisms involving these mutations may provide insights into the pathogenesis of idiopathic PD, it is also possible that different mutations could cause PD via different mechanisms. The autosomal dominant 6055G>A mutation in the LRRK2 gene, which causes a G2019S substitution, is one of the most frequent mutations in familial PD [34]. LRRK2 PD patients are indistinguishable from idiopathic PD, both clinically and in their response to medication [8], [23], [24]. In central Norway about 3% of PD cases have been found to carry the G2019S substitution [8]. In this study we used metabolomic profiling to determine if there are specific metabolomic signatures associated with LRRK2 PD, compared to idiopathic PD. We also addressed the question whether the asymptomatic G2019S mutation carriers could be distinguished by metabolomic analysis from control subjects.
###end p 58
###begin p 59
###xml 30 34 30 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 900 904 900 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 989 994 989 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:9606">patients</span>
Similar to our previous study [14], we found that metabolomic profiles of idiopathic PD are different from those of age matched control subjects. In this study we demonstrated that PD patients with LRRK2 mutations are also different from the control subjects. The separation between PD patients and controls raised the question of whether PD medications caused the distinction. Both idiopathic and LRRK2 PD subjects involved in this study were taking antiparkinsonian medications, and no samples from the unmedicated patients were available. Therefore, it is possible that the observed separation could be related to drug effects, which could involve unknown drug metabolites and drug-induced changes in metabolism. However, we previously demonstrated that metabolomic profiles can differentiate between the medicated PD patients and controls, and this separation is not attributable to drug effects [14]. Additional studies involving a larger population of both medicated and unmedicated LRRK2 PD patients are necessary to address these issues.
###end p 59
###begin p 60
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
We also found that the genetically determined groups could be separated from the non-genetic groups. There was a clear separation between metabolomic profiles of idiopathic and LRRK2 PD patients, and this separation was not attributed to the age differences. Based on the limited number of analytes from plasma we were able to predict whether the patients were from idiopathic PD or from LRRK2 PD groups. PLS-DA models for prediction of the class membership (LRRK2 PD vs. idiopathic PD) were built four times with different subjects from the groups randomly selected for training and prediction sets each time. Although the number of subjects involved in the study was small, the PLS-DA models were able to accurately predict the class membership. Nevertheless, additional experiments with a larger study size are necessary to confirm these findings.
###end p 60
###begin p 61
###xml 59 71 59 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2 G2019S</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
Analysis of metabolomic profiles of the subjects harboring LRRK2 G2019S showed that there were differences dependent on the clinical phenotype: LRRK2 PD patients were partially separated from their healthy family members carrying the mutation. The observation that there is some overlap between the subjects carrying the mutation with LRRK2 PD patients suggests the possibility of developing predictive biomarkers for this group, i.e., who amongst the mutation carriers will develop PD in the future. Longitudinal studies should provide more evidence for this possibility.
###end p 61
###begin p 62
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Bogdanov1">[14]</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Annanmaki1">[35]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-deLau1">[36]</xref>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Ascherio1">[37]</xref>
###xml 649 653 649 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Gao1">[38]</xref>
###xml 818 822 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Schwarzschild1">[39]</xref>
###xml 1339 1344 1339 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 1416 1421 1416 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
###xml 918 924 <span type="species:ncbi:9606">humans</span>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
###xml 1302 1310 <span type="species:ncbi:9606">patients</span>
###xml 1425 1433 <span type="species:ncbi:9606">patients</span>
###xml 1450 1458 <span type="species:ncbi:9606">patients</span>
The majority of the analytes driving separations between the groups were not known. However, the results on known compounds strongly suggest that abnormalities in the purine pathway may be implicated in PD. Similar to the previous studies [14], [35], [36], UA levels were found to be decreased in plasma of PD patients. Several studies provide evidence that UA is involved in the development and progression of PD. Prospective epidemiological studies showed that healthy individuals with higher blood UA levels are at reduced risk for developing PD [37]. A lower risk of PD has been reported among individuals consuming diets that increase serum UA [38]. Higher blood levels of UA in patients recently diagnosed with PD predict a slower rate of disease progression, assessed by both clinical and neuroimaging measures [39]. The mechanisms leading to decreased UA in PD are not known. UA is a major antioxidant, and in humans is the final product of purine metabolism. It is possible that aberrations in the purine pathway in PD could occur upstream from UA. The results of this study support this hypothesis. We found for the first time significant changes in major metabolites of the purine pathway in plasma of PD patients. Notably, hypoxanthine levels were significantly decreased in unmedicated PD patients, as well as in asymptomatic LRRK2 mutation carriers, compared to controls. Xanthine levels were lower in LRRK2 PD patients (but not in IPD patients) as compared to controls. These findings suggest a potential role of the purine pathway in the pathogenesis of PD.
###end p 62
###begin p 63
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007551-Gamache1">[40]</xref>
###xml 336 342 336 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRK2</italic>
In this study LCECA was used for metabolomic profiling. We are currently working on the structural elucidation of unknown biomarkers using different mass spectrometry (MS) approaches [40]. Identification of the individual analytes (potential biomarkers) is crucial since they may play a central role in pathogenesis of the disease. The G2019S substitution in LRRK2 may lead to biochemical changes that are common to PD pathophysiology irrespective of etiology.
###end p 63
###begin p 64
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 324 330 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 442 448 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G2019S</italic>
###xml 839 847 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
###xml 1064 1072 <span type="species:ncbi:9606">patients</span>
An important aspect of this study was to distinguish asymptomatic G2019S carriers, representing a group at risk to develop PD, from controls. Obviously, a genetic test provides complete separation of the mutation carriers from non-carriers. The results of this study do not provide direct evidence for the subsets among the G2019S mutation carriers. Whether metabolomics approach could be used to predict development of PD in a subset of the G2019S carriers remains to be determined. Future longitudinal studies are needed to determine whether one can predict disease penetrance in these subjects. The ability to recognize this group prior to onset of disease indicates the possibility of developing an early diagnostic tool using metabolomics. One could then screen individuals with increased risk of PD including first degree relatives, patients with hyposmia and patients carrying genetic risk factors. Metabolomic profiles could be screened to warn of impending PD symptom onset, and thus allow earlier institution of neuroprotective therapy in presymptomatic patients to slow or prevent nigral cell loss before PD symptomatology becomes evident. Although the present results are promising, this study needs to be repeated in a larger population due to our limitation of a low numbers of cases.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Genetics of Parkinson's disease and parkinsonism.
###end article-title 66
###begin article-title 67
Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder.
###end article-title 67
###begin article-title 68
Review: Familial Parkinson's disease-genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease.
###end article-title 68
###begin article-title 69
Parkinson's disease.
###end article-title 69
###begin article-title 70
G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
###end article-title 70
###begin article-title 71
G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
###end article-title 71
###begin article-title 72
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.
###end article-title 72
###begin article-title 73
Clinical features of LRRK2-associated Parkinson's disease in central Norway.
###end article-title 73
###begin article-title 74
SPECT and PET imaging of the dopaminergic system in Parkinson's disease.
###end article-title 74
###begin article-title 75
Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
###end article-title 75
###begin article-title 76
Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
###end article-title 76
###begin article-title 77
###xml 60 65 <span type="species:ncbi:9606">human</span>
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
###end article-title 77
###begin article-title 78
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.
###end article-title 78
###begin article-title 79
Metabolomic profiling to develop blood biomarkers for Parkinson's disease.
###end article-title 79
###begin article-title 80
Molecular markers of early Parkinson's disease based on gene expression in blood.
###end article-title 80
###begin article-title 81
Metabolomics by numbers: acquiring and understanding global metabolite data.
###end article-title 81
###begin article-title 82
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics.
###end article-title 82
###begin article-title 83
Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders.
###end article-title 83
###begin article-title 84
New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.
###end article-title 84
###begin article-title 85
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.
###end article-title 85
###begin article-title 86
Metabolomic analysis and signatures in motor neuron disease.
###end article-title 86
###begin article-title 87
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles.
###end article-title 87
###begin article-title 88
LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample.
###end article-title 88
###begin article-title 89
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.
###end article-title 89
###begin article-title 90
Diagnostic criteria for Parkinson disease.
###end article-title 90
###begin article-title 91
Simultaneous analysis of the majority of low-molecular-weight, redox-active compounds from mitochondria.
###end article-title 91
###begin article-title 92
Attention to relative response across sequential electrodes improves quantitation of coulometric array.
###end article-title 92
###begin article-title 93
###xml 104 108 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats.
###end article-title 93
###begin article-title 94
Purine catabolism: links to mitochondrial respiration and antioxidant defenses?
###end article-title 94
###begin article-title 95
Multi- and megavariate data analysis: Sweden: Umetrics AB, Malmo.
###end article-title 95
###begin article-title 96
Statistical strategies for avoiding false discoveries in metabolomics and related experiments.
###end article-title 96
###begin article-title 97
Assessing the performance of statistical validaiton tools megavariate metabolomics data.
###end article-title 97
###begin article-title 98
Assessment of PLSDA cross validation.
###end article-title 98
###begin article-title 99
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
###end article-title 99
###begin article-title 100
Low plasma uric acid level in Parkinson's disease.
###end article-title 100
###begin article-title 101
Serum uric acid levels and the risk of Parkinson disease.
###end article-title 101
###begin article-title 102
Urate predicts rate of clinical decline in Parkinson disease.
###end article-title 102
###begin article-title 103
###xml 45 48 <span type="species:ncbi:9606">men</span>
Diet, urate, and Parkinson's disease risk in men.
###end article-title 103
###begin article-title 104
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
###end article-title 104
###begin article-title 105
Metabolomic applications of electrochemistry/mass spectrometry.
###end article-title 105
###begin p 106
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 106
###begin p 107
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the NIH grant 1R21NS060262, the Department of Defense, the Research Council of Norway grant 10314000 and by Reberg's Legacy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 107

